Amprion is passionate about improving patient care through clinical diagnostics and our biopharma partnerships. We are focused on neurodegenerative diseases and believe in doing our best for patients and patient care.
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
